Table. Estimated Response Rates From the NMA of Short-term PASI (Base Case).
| Treatment | Posterior Median, % (95% CrI) | ||
|---|---|---|---|
| PASI 75 | PASI 90 | PASI 100 | |
| Risankizumab-rzaa, 150 mg | 89.2 (86.9-91.3) | 71.6 (67.5-75.4) | 40.4 (35.9-45.0) |
| Ixekizumab, 80 mg | 88.8 (86.5-90.9) | 70.8 (66.8-74.6) | 39.5 (35.2-44.0) |
| Brodalumab, 210 mg | 88.7 (86.5-90.8) | 70.6 (66.8-74.6) | 39.2 (35.2-43.9) |
| Guselkumab, 100 mg | 86.8 (83.8-89.4) | 67.3 (62.5-71.9) | 35.7 (30.9-40.7) |
| Secukinumab, 300 mg | 83.1 (80.2-85.7) | 61.4 (57.2-65.6) | 29.9 (26.3-33.9) |
| Infliximab, 5 mg/kg | 80.4 (76.5-84.0) | 57.4 (52.2-62.8) | 26.5 (22.3-31.4) |
| Certolizumab pegol, 400 mg | 71.1 (65.4-76.5) | 45.6 (39.3-52.2) | 17.7 (13.8-22.3) |
| Ustekinumab, 45 mg ≤100 kg, 90 mg >100 kg | 69.7 (66.3-73.1) | 43.9 (40.2-47.9) | 16.7 (14.4-19.3) |
| Adalimumab, 40 mg | 69.5 (66.0-72.6) | 43.7 (40.0-47.4) | 16.5 (14.2-19.0) |
| Certolizumab pegol, 200 mg | 66.2 (59.6-72.4) | 40.2 (33.5-47.2) | 14.4 (10.7-18.8) |
| Tildrakizumab-asmn, 200 mg | 64.9 (59.4-70.3) | 38.8 (33.3-44.7) | 13.6 (10.6-17.1) |
| Tildrakizumab-asmn, 100 mg | 62.9 (57.3-68.4) | 36.8 (31.4-42.5) | 12.5 (9.7-15.8) |
| Etanercept, 25 mg twice weekly/50 mg once weekly | 40.1 (35.4-45.1) | 17.9 (14.9-21.4) | 4.2 (3.1-5.4) |
| Apremilast, 30 mg | 30.8 (26.8-35.0) | 12.1 (9.9-14.7) | 2.4 (1.8-3.1) |
| Dimethyl fumarate | 29.6 (22.0-38.3) | 11.4 (7.5-16.7) | 2.2 (1.2-3.8) |
| Placebo | 5.3 (4.8-5.9) | 1.1 (1.0-1.3) | 0.1 (0.1-0.1) |
Abbreviations: CrI, credible interval; NMA, network meta-analysis; PASI, Psoriasis Area and Severity Index; PASI 75, 90, 100, a 75%, 90% or 100% decrease from baseline PASI.